Dynamic Advisor Solutions LLC Purchases 1,377 Shares of Enovis Co. (NYSE:ENOV)

Dynamic Advisor Solutions LLC grew its position in shares of Enovis Co. (NYSE:ENOV) by 7.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 18,999 shares of the company’s stock after buying an additional 1,377 shares during the quarter. Dynamic Advisor Solutions LLC’s holdings in Enovis were worth $834,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ENOV. Pinnacle Bancorp Inc. increased its position in shares of Enovis by 54.5% during the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock valued at $37,000 after acquiring an additional 300 shares during the last quarter. Aigen Investment Management LP increased its position in shares of Enovis by 5.1% during the 3rd quarter. Aigen Investment Management LP now owns 8,859 shares of the company’s stock valued at $381,000 after purchasing an additional 430 shares during the last quarter. UMB Bank n.a. raised its stake in shares of Enovis by 128.2% during the 4th quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after purchasing an additional 437 shares during the period. FMR LLC boosted its holdings in shares of Enovis by 20.5% in the 3rd quarter. FMR LLC now owns 2,840 shares of the company’s stock worth $122,000 after buying an additional 484 shares during the last quarter. Finally, Heritage Family Offices LLP grew its position in Enovis by 16.6% during the fourth quarter. Heritage Family Offices LLP now owns 5,585 shares of the company’s stock valued at $245,000 after buying an additional 794 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Stock Performance

Shares of ENOV stock opened at $47.78 on Monday. The firm’s 50 day moving average is $45.93 and its 200 day moving average is $44.46. The stock has a market capitalization of $2.67 billion, a P/E ratio of -21.82 and a beta of 1.94. Enovis Co. has a 12 month low of $38.27 and a 12 month high of $65.03. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40.

Enovis (NYSE:ENOV) last posted its earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.11. The firm had revenue of $505.22 million for the quarter, compared to the consensus estimate of $504.44 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The business’s quarterly revenue was up 21.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.56 earnings per share. On average, sell-side analysts anticipate that Enovis Co. will post 2.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have commented on ENOV shares. JMP Securities initiated coverage on shares of Enovis in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $62.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $65.00 price target on shares of Enovis in a report on Thursday, November 7th. Finally, Evercore ISI dropped their price objective on Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Enovis presently has an average rating of “Moderate Buy” and a consensus target price of $65.86.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.